CDH5 and neoplasm: The discovery of a monoclonal antibody directed against an extracellular epitope that is only accessible in ECs forming new angiogenic networks has allowed specific targeting of VE-cadherin in the tumor vasculature, despite ubiquitous VE-cadherin expression in normal vessels [8,9,10,11,12].